Financial PerformanceNiagen Bioscience reported encouraging financial results with top-line revenue totaling $34M, surpassing forecasts.
Intellectual PropertyNiagen becomes the sole owner of additional nicotinamide riboside patents, enhancing IP protection from competitors.
Product LaunchThe launch of Tru Niagen Beauty in the US expands Niagen's market into the fast-growing 'internal beauty' category.